

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/722,176
Filing Date	2003-11-24
First Named Inventor	RANA, Tariq M.
Art Unit	1635
Examiner Name	CHONG, K.
Attorney Docket Number	20336-00016

Sheet	1	of	1
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DALLAS, A., and VLASSOV, A.V., RNAi: a novel antisense technology and its therapeutic potential, Medical Science Monitor, 2006, 12(4): RA67-74.	
		HU, Q., et al., Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human ... Nucleic Acids Res., 2002, 30(16):3632-41.	
		MARCUSSON, E.G., et al., Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus, Nucleic Acids Res., 1998, 26(8):2016-2023.	
		Merck Index, 14th Edition, 2006, Whitehouse Station, NJ, "Ibuprofen," p. 847 and "Thymidine," pp 1614-1615.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.